<SEC-DOCUMENT>0001437749-20-010444-index.html : 20200512 <SEC-HEADER>0001437749-20-010444.hdr.sgml : 20200512 <ACCEPTANCE-DATETIME>20200512165237 ACCESSION NUMBER: 0001437749-20-010444 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 5 CONFORMED PERIOD OF REPORT: 20200506 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200512 DATE AS OF CHANGE: 20200512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NAVIDEA BIOPHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000810509 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 311080091 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35076 FILM NUMBER: 20869773 BUSINESS ADDRESS: STREET 1: 4995 BRADENTON AVENUE STREET 2: SUITE 240 CITY: DUBLIN STATE: OH ZIP: 43017 BUSINESS PHONE: 6147937500 MAIL ADDRESS: STREET 1: 4995 BRADENTON AVENUE STREET 2: SUITE 240 CITY: DUBLIN STATE: OH ZIP: 43017 FORMER COMPANY: FORMER CONFORMED NAME: NEOPROBE CORP DATE OF NAME CHANGE: 19940714 </SEC-HEADER> <DOCUMENT> <TYPE>8-K <SEQUENCE>1 <FILENAME>navb20200511_8k.htm <DESCRIPTION>FORM 8-K <TEXT> Document 1 - file: navb20200511_8k.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-3.1 <SEQUENCE>2 <FILENAME>ex_186252.htm <DESCRIPTION>EXHIBIT 3.1 <TEXT> Document 2 - file: ex_186252.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-10.1 <SEQUENCE>3 <FILENAME>ex_186253.htm <DESCRIPTION>EXHIBIT 10.1 <TEXT> Document 3 - file: ex_186253.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-10.2 <SEQUENCE>4 <FILENAME>ex_186254.htm <DESCRIPTION>EXHIBIT 10.2 <TEXT> Document 4 - file: ex_186254.htm
</DOCUMENT> <DOCUMENT> <TYPE>EX-99.1 <SEQUENCE>5 <FILENAME>ex_186255.htm <DESCRIPTION>EXHIBIT 99.1 <TEXT> Document 5 - file: ex_186255.htm
</DOCUMENT> </SEC-DOCUMENT>